SCHEMBL25632913

SCHEMBL25632913

CCOC(=O)/C(=C\CN(C)C)c1c(C(C)(C)CNC(=O)OC(C)(C)C)c(-c2ccc(F)cc2)nn1Cc1ccc(OC)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.37
ALDH1A1 P00352 4/20 0.33
MAPT P10636 2/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ACHE P22303 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
CASP1 P29466 3/20 0.33
CASP7 P55210 2/20 0.33
HIF1A Q16665 2/20 0.33
CYP1A2 P05177 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CACNA1G O43497 1/20 0.33
ASIC1 P78348 1/20 0.33
GLA P06280 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
GNRHR P30968 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17777930 0.92 KCNK3 (0.38) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL19711705 0.86 KCNK3 (0.40) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL17777810 0.81 ASIC1 (0.36) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL17777971 0.81 KCNK3 (0.39) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL21451580 0.76 ASIC1 (0.37) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL17777768 0.75 PTGDR2 (0.36) ALDH1A1MAPTLMNAKMT2AMKNK2
SCHEMBL17777908 0.75 ASIC1 (0.37) KCNK3ALDH1A1MAPTLMNAMEN1
SCHEMBL19702812 0.71 PTGDR2 (0.35) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL17777764 0.69 PTGDR2 (0.42) ALDH1A1MAPTMEN1KMT2AMKNK2
SCHEMBL19702814 0.67 PTGDR2 (0.35) ALDH1A1LMNAMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183247-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS LTD (GB) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183247-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS KCNK3 4151/4885ALDH1A1 1592/4885MAPT 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.